DaVita Inc. $DVA Shares Sold by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership decreased its position in shares of DaVita Inc. (NYSE:DVA) by 6.7% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 1,110,151 shares of the company’s stock after selling 79,849 shares during the period. Arrowstreet Capital Limited Partnership’s holdings in DaVita were worth $170,619,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Root Financial Partners LLC lifted its stake in shares of DaVita by 128.0% during the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after purchasing an additional 105 shares during the period. Caitlin John LLC purchased a new stake in shares of DaVita in the fourth quarter valued at $34,000. Sankala Group LLC acquired a new position in DaVita in the fourth quarter valued at $39,000. Canada Pension Plan Investment Board purchased a new position in DaVita during the second quarter worth about $43,000. Finally, Kestra Advisory Services LLC acquired a new stake in DaVita in the 4th quarter worth about $45,000. 90.12% of the stock is owned by hedge funds and other institutional investors.

DaVita Price Performance

NYSE DVA opened at $235.46 on Friday. The company has a market capitalization of $15.12 billion, a price-to-earnings ratio of 21.84, a price-to-earnings-growth ratio of 0.77 and a beta of 0.88. DaVita Inc. has a 12 month low of $101.00 and a 12 month high of $239.64. The company’s fifty day moving average price is $213.62 and its two-hundred day moving average price is $168.71.

DaVita (NYSE:DVA) last issued its earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The business had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. During the same quarter in the prior year, the business posted $2.00 EPS. The company’s revenue for the quarter was up 6.0% on a year-over-year basis. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, analysts anticipate that DaVita Inc. will post 15.07 EPS for the current year.

Insider Activity

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the transaction, the chief financial officer owned 132,434 shares of the company’s stock, valued at $25,440,571.40. This trade represents a 27.99% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the transaction, the insider owned 109,194 shares of the company’s stock, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their position. The SEC filing for this sale provides additional information. 1.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several analysts have commented on DVA shares. Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a report on Monday, June 8th. Truist Financial raised their target price on shares of DaVita from $205.00 to $250.00 and gave the stock a “hold” rating in a research report on Tuesday, July 14th. Zacks Research downgraded shares of DaVita from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. TD Cowen increased their price target on shares of DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research note on Monday, May 11th. Finally, UBS Group upped their price objective on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Two research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $216.50.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.